Fierce Biotech Fundraising Tracker '26: NeuShen nets $80M; Superluminal snags $60M Read more →
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies Read more →
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial Read more →
